# iShares NASDAQ US Biotechnology UCITS ETF (BTEE) **Source:** https://fundology.uk/fund/btee · ISIN IE00BDZVHG35 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 30/09/2026, BTEE (iShares NASDAQ US Biotechnology UCITS ETF, ISIN IE00BDZVHG35) closed at $10.39 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the five years to 30/09/2026 its total return was +44.4%, or +12.9% after UK CPIH inflation. ## Summary iShares NASDAQ US Biotechnology UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2018. It tracks the NASDAQ / Biotechnology. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is paid out to holders as cash, usually a few times a year. Latest close: **$10.39** (30/09/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | BTEE | | ISIN | IE00BDZVHG35 | | Category | Technology | | Type | ETF | | Provider | iShares | | Tracks | NASDAQ / Biotechnology | | Income | Distributing | | Ongoing charge | 0.35% a year (£35 per £10,000) | | Fund size | £46.7m | | Launched | 2018 | | Domicile | Ireland | ## Past returns (periods to 30/09/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +49.51% | +44.82% | income reinvested | | 3 years | +68.02% | +51.61% | income reinvested | | 5 years | +44.36% | +12.85% | income reinvested | Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published. ## Calendar-year returns Calendar-year returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price only, income paid out not included): 2022 −1.7%, 2023 −0.3%, 2024 +0.3%, 2025 +23.7%; 2026 to 30/09/2026 +25.5%. Returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price only, income paid out not included) over the 12 months to 30/09/2026: +52.1%; to 30/09/2025: −0.7%; to 30/09/2024: +10.2%; to 30/09/2023: −7.0%; to 30/09/2022: −10.4%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2022 | -1.7% | -10.0% | Price | | 2023 | -0.3% | -4.3% | Price | | 2024 | +0.3% | -3.1% | Price | | 2025 | +23.7% | +19.5% | Price | | 2026 to 30/09/2026 | +25.5% | +22.0% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 18.71% | -5.77% | | 3 years | 19.46% | -23.74% | | 5 years | 18.92% | -23.74% | ## Largest fall Volatility of iShares NASDAQ US Biotechnology UCITS ETF in pounds, annualised from weekly returns to 30/09/2026: 18.7% over 1 year, 19.5% over 3 years, 18.9% over 5 years. Largest fall in the price of iShares NASDAQ US Biotechnology UCITS ETF since October 2021, in pounds: −23.7% from 26/07/2024 to 11/04/2025. The lowest 12-month return of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price only, income paid out not included) since January 2021 was −22.0% (12 months to 18/02/2022); the highest was +60.0% (12 months to 03/07/2026). On 30/09/2026 the price of iShares NASDAQ US Biotechnology UCITS ETF was at its highest weekly close since October 2021, in pounds. ## Charges compared with similar funds Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year, as of 01/10/2026: 92 of the 118 other technology funds charge more, 8 the same and 18 less (share classes counted once). ## Funds tracking the same index 3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (30/09/2026). | Fund | Ongoing charge | 1 year | 3 years | 5 years | |---|---|---|---|---| | Invesco NASDAQ Biotech UCITS ETF | 0.40% | +46.1% | +62.3% | +35.2% | | iShares NASDAQ US Biotechnology UCITS ETF (this fund) | 0.35% | +49.5% | +68.0% | +44.4% | | iShares NASDAQ US Biotechnology UCITS ETF | 0.35% | +50.0% | +68.0% | +45.9% | Returns are the data vendor’s, in pounds, income reinvested unless marked "(price)". ## Charges & eligibility - Ongoing charges figure (OCF): **0.35%** per year - ISA eligible: yes - SIPP eligible: yes --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.